Clinical trial · Observational
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): According to the NIH definition of clinical trial studies, this study does not meet requirement to be a clinical trial study.
Summary
Brief summary (as posted)
The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diffuse Optical Spectroscopy Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Diagnostic Tool
- description
- Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
- interventionNames
- Device: Diffuse Optical Spectroscopy Imaging
Primary outcomes (1)
- measure
- Diagnostic Tool Breast Cancer Response to Neoadjuvant Chemotherapy
- timeFrame
- up to 12 months
- description
- Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female, 18 years of age or older, non pregnant or nursing. * Diagnosis of breast cancer and will be receiving chemo therapy treatments Exclusion Criteria: * 18 years of age or younger, pregnant or nursing. * Previous treatment including chemo therapy, radiation, surgery, and hormone therapy. * Previous diagnosis with other form of cancer.
References
Publications (0)
Data not yet available